Novel. Prevalent. Actionable.
We are advancing a growing pipeline of novel and prevalent therapeutic targets across oncology, neurodegeneration, and other high-need indications, with attributes that enable the next generation of highly efficacious and safe precision medicines.
IN SILICO DISCOVERYEXPERIMENTAL VALIDATIONPRECLINICAL
CNS
ALS: ALS-101
ONCOLOGY
Breast CancerLung CancerMetastatic Colorectal CancerAMLMultiple Myeloma